AstraZeneca Eesti OÜ
AstraZeneca Eesti OÜ is a OÜ based in Tallinn, registry code 11733875, status: active. Main activity: Other business support service activities n.e.c.. According to EMTA, turnover for Q3 2026 was €1 850 148 with 47 employees.
Q3 2026 · data from the Tax and Customs Board (EMTA)
Position in the industry
- Turnover · Q3 2026 1.9 mn €above 98% of companiesindustry median 14 685 € · companies in the industry: 1 227
- Labour taxes per employee 9 605 €above 98% of companiesindustry median 1 350 € · companies in the industry: 777
- Revenue · 2025 7 mn €above 98% of companiesindustry median 3 483 € · companies in the industry: 3 688
- Net profit margin · 2025 5.6 %above 41% of companiesindustry median 11.2 % · companies in the industry: 2 113
Taxes and turnover
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Quarter | Turnover, € | State taxes, € | Labour taxes, € | Employees |
|---|---|---|---|---|
| Q3 2026 | 1 850 148 | 438 231 | 451 443 | 47 |
| Q2 2026 | 1 948 724 | 694 225 | 722 105 | 47 |
| Q1 2026 | 1 692 131 | 365 564 | 377 589 | 50 |
| Q4 2025 | 1 909 477 | 438 532 | 437 741 | 44 |
| Q3 2025 | 1 802 078 | 427 909 | 446 826 | 58 |
| Q2 2025 | 1 931 685 | 698 790 | 732 093 | 45 |
| Q1 2025 | 1 526 637 | 351 255 | 364 634 | 49 |
| Q4 2024 | 1 380 973 | 349 002 | 362 932 | 43 |
| Q3 2024 | 1 713 173 | 370 033 | 387 680 | 43 |
| Q2 2024 | 1 581 473 | 561 906 | 581 548 | 41 |
| Q1 2024 | 1 451 058 | 317 962 | 319 665 | 46 |
| Q4 2023 | 1 318 384 | 311 531 | 309 636 | 50 |
| Q3 2023 | 1 321 340 | 287 717 | 294 612 | 44 |
| Q2 2023 | 1 310 461 | 423 901 | 435 864 | 39 |
| Q1 2023 | 1 140 698 | 239 505 | 237 630 | 43 |
| Q4 2022 | 916 951 | 242 779 | 248 166 | 39 |
| Q3 2022 | 1 166 222 | 222 063 | 226 216 | 40 |
| Q2 2022 | 991 649 | 329 214 | 347 013 | 39 |
| Q1 2022 | 1 051 990 | 213 599 | 221 008 | 39 |
Q3 2026 · calculated from EMTA data
Financials by year
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
- Company
- Industry median
Industry: Office administrative, office support and other business support activities (the EMTAK division of the main activity). Median: half of the industry is above, half below.
| Year | Revenue, € | Net profit, € | Labour costs, € | Assets, € | Equity, € | Employees |
|---|---|---|---|---|---|---|
| 2025 | 6 969 720 | 393 516 | 4 615 798 | 5 494 103 | 3 718 350 | 44 |
| 2024 | 6 287 586 | 306 284 | 4 395 114 | 4 922 264 | 3 324 834 | 41 |
| 2023 | 5 087 993 | 286 262 | 3 608 976 | 4 283 542 | 3 018 550 | 37 |
| 2022 | 3 959 038 | 295 388 | 2 557 797 | 3 839 304 | 2 732 288 | 32 |
| 2021 | 3 045 823 | 249 746 | 2 049 168 | 3 189 226 | 2 436 900 | 29 |
| 2020 | 2 330 565 | 162 948 | 1 716 929 | 2 745 796 | 2 187 154 | 29 |
| 2019 | 2 335 467 | 85 301 | 1 527 627 | 2 435 819 | 2 024 206 | 25 |
| 2018 | — | — | — | — | — | 26 |
| 2017 | — | — | — | — | — | 29 |
| 2016 | — | — | — | — | — | 28 |
| 2015 | — | — | — | — | — | 30 |
| 2014 | — | — | — | — | — | 31 |
| 2013 | — | — | — | — | — | 29 |
| 2012 | — | — | — | — | — | 27 |
| 2011 | — | — | — | — | — | 27 |
| 2010 | — | — | — | — | — | 34 |
Figures from the company’s own (non-consolidated) balance sheet and income statement. A loss is shown with a minus sign.
Financial ratios for 2025
Annual reports
| Year | Period | Filed | Report | Documents |
|---|---|---|---|---|
| 2025 | 1 Jan 2025 – 31 Dec 2025 | 19 Jun 2026 | Company’s own · audited | e-Äriregister |
| 2024 | 1 Jan 2024 – 31 Dec 2024 | 19 Jun 2025 | Company’s own · audited | e-Äriregister |
| 2023 | 1 Jan 2023 – 31 Dec 2023 | 28 Jun 2024 | Company’s own · audited | e-Äriregister |
| 2022 | 1 Jan 2022 – 31 Dec 2022 | 30 May 2023 | Company’s own · audited | e-Äriregister |
| 2021 | 1 Jan 2021 – 31 Dec 2021 | 30 Jun 2022 | Company’s own · audited | e-Äriregister |
| 2020 | 1 Jan 2020 – 31 Dec 2020 | 29 Jun 2021 | Company’s own · audited | e-Äriregister |
| 2019 | 1 Jan 2019 – 31 Dec 2019 | 25 Jun 2020 | Company’s own · audited | e-Äriregister |
Board
- Kati NaberBoard member · since 12 Oct 2018
- Michal WronkaBoard member · since 16 Aug 2024
- Triin ParikBoard member · since 7 Feb 2025
- Nasdaq CSD SEKeeper of the share register · since 28 Sep 2017
- Jesper BergkvistProcurator · since 23 Sep 2014
Right of representation
Any member of the management board may represent the private limited company in all transactions.
Any procurator may represent the private limited company in all legal acts related to its business. A procurator may transfer or encumber immovable property only if that right is entered on the registry card.
Owners
- Omanikukonto: ASTRAZENECA CONTINENT B.V.Legal person · 690 246 €
Beneficial owners
- Michel DemaréMember of a senior management body (management or supervisory board) · BEL · since 6 Jun 2024
Founders and other persons
- AstraZeneca Continent B.V.Founder · 10 800 000 € · 16 Oct 2009
- Aktsiaselts PricewaterhouseCoopersAudit firm · 7 Sep 2017
Activities (EMTAK)
- 82991Other business support service activities n.e.c. Main
Rulings
All rulings (PDF)| Number, date | Title | Deadline | State | Document |
|---|---|---|---|---|
| Ä 10135171 / 19 7 Feb 2025 |
Amendment entry | In force 7 Feb 2025 |
||
| Ä 10135171 / 18 16 Aug 2024 |
Amendment entry | In force 16 Aug 2024 |
||
| Ä 10135171 / 17 16 Dec 2021 |
Amendment entry | In force 16 Dec 2021 |
||
| Ä 10135171 / 16 30 Nov 2018 |
Amendment entry | In force 30 Nov 2018 |
||
| Ä 10135171 / 15 12 Oct 2018 |
Amendment entry | In force 12 Oct 2018 |
||
| Ä 10135171 / 14 17 Jan 2018 |
Amendment entry | In force 17 Jan 2018 |
||
| Ä 10135171 / 13 1 Dec 2017 |
Amendment entry | In force 1 Dec 2017 |
||
| Ä 10135171 / 12 28 Sep 2017 |
Amendment entry | In force 28 Sep 2017 |
||
| Ä 10135171 / 11 11 Sep 2017 |
Amendment entry | In force 11 Sep 2017 |
||
| Ä 10135171 / 10 30 May 2017 |
Amendment entry | In force 30 May 2017 |
||
| Ä 10135171 / 9 31 Aug 2016 |
Amendment entry | In force 31 Aug 2016 |
||
| Ä 10135171 / 8 10 Sep 2015 |
Amendment entry | In force 10 Sep 2015 |
||
| Ä 10135171 / 7 23 Sep 2014 |
Amendment entry | In force 23 Sep 2014 |
||
| Ä 10135171 / M4 16 Sep 2014 |
Procedural ruling | In force 16 Sep 2014 |
||
| Ä 10135171 / 6 11 Feb 2013 |
Amendment entry | In force 11 Feb 2013 |
||
| Ä 10135171 / M3 1 Feb 2013 |
Ruling to eliminate deficiencies | 5 Mar 2013 | In force 1 Feb 2013 |
|
| Ä 10135171 / 5 24 May 2012 |
Amendment entry | In force 24 May 2012 |
||
| Ä 10135171 / 4 19 Apr 2012 |
Entry refused: deficiencies not eliminated | 24 May 2012 | In force 9 May 2012 |
|
| Ä 10135171 / M2 21 Feb 2012 |
Ruling to eliminate deficiencies | 2 Apr 2012 | In force 21 Feb 2012 |
|
| Ä 10135171 / 3 14 Jul 2011 |
Amendment entry | In force 14 Jul 2011 |
||
| Ä 10135171 / M1 11 May 2011 |
Ruling to eliminate deficiencies | 14 Jun 2011 | In force 11 May 2011 |
|
| Ä 135171 / 2 12 Jan 2010 |
Note on registration of shares in the Estonian central register of securities | In force 12 Jan 2010 |
||
| Ä 135171 16 Oct 2009 |
First entry | In force 16 Oct 2009 |
Sources: e-Äriregister and EMTA. Data updated 30 Oct 2026. Open at the source ↗ · Report an error in the data